$JNJJOHNSON & JOHNSON

📅 Upcoming

🕒 Recent(90d)

News

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 7d ago
• Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy
  Key leaders Kenneth Greenberg (CEO), Steve Feinstein (CSO) Headquarters San Francisco Total raised $186M Key investors Vida Ventures, ARCH Ventures Partners, Illumina Ventures, Leaps by Bayer, John…
  endpoints · 9d ago
• J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
  Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
  biospace · 9d ago
• Indivior ends PAM drug collab with Addex ahead of Supernus merger
  Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs).
  fiercebiotech · 10d ago
• The human cost of AI interviews
  While artificial intelligence can help biotech and pharma companies more quickly vet job applicants, it can also turn off the very people they want to employ. Two recruiting experts discuss AI’s ro…
  biospace · 11d ago
• Growth mode: 3 biotechs that are staffing up after series B raises
  Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
  biospace · 11d ago
• Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
  Two former FDA commissioners: Heidi Overton is the right pick in a difficult moment.
  stat · 12d ago
• An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
  Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
  biopharma_dive · 12d ago